Kensey Nash Extracts Biomaterials Growth To Curb Reliance On Angio-Seal
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash likely will pursue an acquisition strategy and an expanded client base to leverage its biomaterial patents and manufacturing capability
You may also be interested in...
Kensey Nash Touts Prospects For TriActiv Embolic Protection Device
Kensey Nash believes the embolic protection market for saphenous vein graft procedures will double to more than $200 mil. in the next few years as physicians use distal protection to diminish their exposure to litigation
Kensey Nash Touts Prospects For TriActiv Embolic Protection Device
Kensey Nash believes the embolic protection market for saphenous vein graft procedures will double to more than $200 mil. in the next few years as physicians use distal protection to diminish their exposure to litigation
Distal protection device submission
Kensey Nash projects a July 510(k) submission for its TriActiv saphenous vein graft surgery distal protection device. The firm expects clearance this year, but no longer anticipates launching the system by the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. in September, as Kensey Nash previously stated in January. Former estimates were based on the assumption that a 510(k) based on the 894-patient PRIDE trial would be filed in April (1"The Gray Sheet" Jan. 26, 2004, p. 5)...